OtherBasic Science Investigations
Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer
Chaitanya R. Divgi, Joseph A. O’Donoghue, Sydney Welt, Jayne O’Neel, Ron Finn, Robert J. Motzer, Achim Jungbluth, Eric Hoffman, Gerd Ritter, Steve M. Larson and Lloyd J. Old
Journal of Nuclear Medicine August 2004, 45 (8) 1412-1421;
Chaitanya R. Divgi
Joseph A. O’Donoghue
Sydney Welt
Jayne O’Neel
Ron Finn
Robert J. Motzer
Achim Jungbluth
Eric Hoffman
Gerd Ritter
Steve M. Larson
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer
Chaitanya R. Divgi, Joseph A. O’Donoghue, Sydney Welt, Jayne O’Neel, Ron Finn, Robert J. Motzer, Achim Jungbluth, Eric Hoffman, Gerd Ritter, Steve M. Larson, Lloyd J. Old
Journal of Nuclear Medicine Aug 2004, 45 (8) 1412-1421;
Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer
Chaitanya R. Divgi, Joseph A. O’Donoghue, Sydney Welt, Jayne O’Neel, Ron Finn, Robert J. Motzer, Achim Jungbluth, Eric Hoffman, Gerd Ritter, Steve M. Larson, Lloyd J. Old
Journal of Nuclear Medicine Aug 2004, 45 (8) 1412-1421;
Related Articles
Cited By...
- In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
- Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma
- Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250
- Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma
- Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors
- A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
- A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma
- Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience
- Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478
- Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity
- Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response
- Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With 131I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma
- Radioimmunotherapy of Prostate Cancer: Does Tumor Size Matter?
- Radioimmunotherapy for Colorectal Cancer
- Current Status of Therapy of Solid Tumors